Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

p> Marketing, general

and administrative 11,198 11,170 2,400 2,945

Total operating

expenses 46,062 42,220 10,164 10,625

Interest income 1,786 2,648 363 644

Interest expense (1,053) (834) (281) (191)

Other expense (66) (105) (66) (76)

Change in valuation of

warrants 2,314 - 2,314 -

Total other income

(expense), net 2,981 1,709 2,330 377

Net loss $(43,081) $(40,511) $(7,834) $(10,248)

Historical net

loss per share:

Basic and diluted $(1.28) $(1.49) $(0.21) $(0.35)

Weighted-average

shares -

basic and

diluted 33,581,590 27,247,385 38,112,063 28,931,495

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF CASH FLOWS

(in thousands)

Years ended December 31,

2007 2006

(unaudited)

Operating activities:

Net loss $(43,081) $(40,511)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 3,449 2,133

Stock-based compensation 4,584 4,010

Amortization of premium/discount on short-term

investments (412) (638)

Change in valuation of warrants (2,314) -

Other
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 New ... Imperial Innovations, Cambridge Innovation Capital and Johnson & ... cancer genomics company focused on harnessing the potential ... cancer testing and treatment, today announced it has ... Imperial Innovations and including Cambridge Innovation Capital and ...
(Date:9/22/2014)... and SANTA CLARA, Calif. , ... WBMD ), the leading source of health ... WebMD/Medscape survey that provide novel insights regarding physician ... diagnosis and care.  Dr. Eric Topol , a ... medicine, who serves as both Editor-in-Chief of Medscape and ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... University of Minnesota electrical engineering researchers have developed ... time demonstrates mechanical transportation of light. The discovery ... more efficient optical devices for computation and communication. ... electrical and computer engineering assistant professor Mo Li ... published online and will appear in the October ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 2WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 3WebMD/Medscape Digital Technology Survey Reveals Unique Insights Into How Patients and Physicians Perceive the Role, Potential and Risks Associated with Digital Health Technologies 4Platelets modulate clotting behavior by 'feeling' their surroundings 2Engineers show light can play seesaw at the nanoscale 2
... KENILWORTH and WHITEHOUSE STATION, N.J., April 25 ,Schering-Plough/MERCK ... letter from the U.S. Food and Drug Administration,(FDA) ... montelukast for,the treatment of allergic rhinitis symptoms in ... New Drug Application filing for loratadine/montelukast was accepted,by ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) announced today that it ... that the Company is not in,compliance with the $1.00 ... Global Market pursuant to Marketplace Rule 4450,(a)(5). This notification, ... is a standard communication when the bid price of ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... the consumer and professional markets, announced,today that it ... Conference being held April 30 - May 2, ... Zwanziger, Chief Executive Officer, will,attend. His presentation is ...
Cached Biology Technology:Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 2Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast 3Keryx Biopharmaceuticals Receives Nasdaq Notification 2Keryx Biopharmaceuticals Receives Nasdaq Notification 3
(Date:9/23/2014)... Company has secured $21 million in a Series C ... the Company,s cancer immunotherapy pipeline and advance its lead ... the round, with participation from Majuven and all existing ... Harbinger Venture Capital. , Eureka is engaged in ... mimic the functions of a T cell receptor, a ...
(Date:9/23/2014)... of scientists has identified a gene mutation that ... which the bone marrow fails to produce normal ... which three generations had blood disorders, the researchers ... telomeres, chromosomal structures with crucial roles in normal ... help suggest future molecular-based treatments that bypass the ...
(Date:9/23/2014)... the development of animals and plants. The central problem ... translated in a reliable manner to give specific spatial ... of stripe formation is a classic paradigm in developmental ... the French flag, is caused by a gradient of ... low concentrations of the morphogen a "blue", "white" or ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Recreating the stripe patterns found in animals by engineering synthetic gene networks 2
... the cacao genome is complete, a consortium of academic, ... scientists performed much of the sequencing work, which is ... website of the Cacao Genome Database project. Despite ... Inc., Cacao Genome Database scientists say one of their ...
... , BOSTON (9-15-10) -- A team led by Boston ... four-year grant from the National Institutes of Health to ... could lead to individual genome sequencing for less than ... on an initial, $2.2 million NIH grant and led ...
... 15 September 2010 -- The European Society for Medical Oncology ... the advancement of medical research. The awards will be presented ... 35th ESMO Congress, to take place from 8-12 October in ... the 2010 ESMO Award for his key role in the ...
Cached Biology News:Chocolate farmers could benefit from newly sequenced cacao genome 2Chocolate farmers could benefit from newly sequenced cacao genome 3Chocolate farmers could benefit from newly sequenced cacao genome 4BU team wins $4.1M genome grant 2Top cancer specialists receive ESMO awards 2Top cancer specialists receive ESMO awards 3Top cancer specialists receive ESMO awards 4
... synthetic peptide whose sequence is from the C-terminal end of the mouse ... from amino acids 429 to 448 of RAR*. The sequence of ... V - S - P - S - S - V - ... Q - S - P - L - L - Q ...
... The ELx50 is a fast and ... equipped with our patented Dual-ActionTM 16-channel manifold. ... of the dispense and aspiration manifolds for ... 96- and 384-well formats. The problem of ...
... commonly used as a fusion partner when ... GSTTag sequence has been reported to enhance ... solubility of its fusion partners. When expressed ... fusion proteins can be purified with immobilized ...
... 1200L sets the new standard for ... incorporating the latest technologies and providing ... analytical needs. The Atmospheric Pressure ... Quadrupole Analyzer provide superior selectivity and ...
Biology Products: